The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
Sign in to access this content
Sign InAmid a robust period for biopharmaceutical sales, Genmab announced that worldwide net trade sales of DARZALEX reached $4,207 million in the second quarter of 2026. This performance, reported by its partner Johnson & Johnson, stems from the daratumumab product line, including subcutaneous formulations that carry royalty obligations. The announcement highlights the drug's sustained commercial momentum as a cornerstone treatment in its therapeutic class.
This sales milestone reinforces DARZALEX's competitive position against peers like Sanofi's Sarclisa in the multiple myeloma market. Per market data, JNJ shares closed at $253.85 (close July 14, 2026), with investors assessing how these royalty-bearing sales will impact the broader pharmaceutical segment's bottom line. The figures align with a trend of continued growth for high-demand biologic therapies in the current fiscal year.
Looking ahead, market participants will monitor Genmab's upcoming full financial reports to gauge the exact royalty income derived from these sales. With JNJ priced at $253.85 (close July 14, 2026), and no immediate sector-specific catalysts in the upcoming economic calendar, the focus remains on the drug's ability to maintain its market share and the potential for further label expansions.